Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
Open Access
- 14 January 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (1), 223
- https://doi.org/10.3390/jcm9010223
Abstract
Until recently, distant metastatic melanoma was considered refractory to systemic therapy. A better understanding of the interactions between tumors and the immune system and the mechanisms of regulation of T-cells led to the development of immune checkpoint inhibitors. This review summarizes the current novel data on the treatment of metastatic melanoma with anti-programmed cell death protein 1 (PD-1) antibodies and anti-PD-1-based combination regimens, including clinical trials presented at major conference meetings. Immune checkpoint inhibitors, in particular anti-PD-1 antibodies such as pembrolizumab and nivolumab and the combination of nivolumab with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab can achieve long-term survival for patients with metastatic melanoma. The anti-PD-1 antibodies nivolumab and pembrolizumab were also approved for adjuvant treatment of patients with resected metastatic melanoma. Anti-PD-1 antibodies appear to be well tolerated, and toxicity is manageable. Nivolumab combined with ipilimumab achieves a 5 year survival rate of more than 50% but at a cost of high toxicity. Ongoing clinical trials investigate novel immunotherapy combinations and strategies (e.g., Talimogene laherparepvec (T-VEC), Bempegaldesleukin (BEMPEG), incorporation or sequencing of targeted therapy, incorporation or sequencing of radiotherapy), and focus on poor prognosis groups (e.g., high tumor burden/LDH levels, anti-PD-1 refractory melanoma, and brain metastases).Keywords
This publication has 69 references indexed in Scilit:
- Prognosis of Acral Melanoma: A Series of 281 PatientsAnnals of Surgical Oncology, 2013
- Tumor Immunotherapy Directed at PD-1The New England Journal of Medicine, 2012
- Mutations inGNA11in Uveal MelanomaThe New England Journal of Medicine, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- Distinct Sets of Genetic Alterations in MelanomaThe New England Journal of Medicine, 2005
- Use of Magnetic Resonance Imaging to Assess Blood-Brain/Blood-Glioma Barrier Opening During Conformal RadiotherapyJournal of Clinical Oncology, 2005
- Incidence of noncutaneous melanomas in the U.S.Cancer, 2005